Impact of Pharmacogenomics Testing on Response to Antidepressants and Antipsychotics – A Systematic Review
DOI:
https://doi.org/10.56570/jimgs.v1i1.154Keywords:
Precision medicine, personalized medicine, pharmacogenomics testing, individualized medicine, predictive medicine and Antidepressant DrugAbstract
Introduction: With the sequencing of the human genome and the subsequent revelation of the genetic structures underlying many complex illnesses and responses to many treatments, precision medicine has emerged as a new player in the healthcare setting. We aimed to assess the Impact of pharmacogenomics testing on response to Antidepressants and Antipsychotics. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used in this systematic review. This systematic review identified PubMed, PMC, and Medical Literature Analysis and Retrieval System Online (MEDLINE), Supplementation of the available articles for the review was done using Google Scholar and Research Gate. Results: Ten study articles were included after analyzing 12408 papers. These studies were gathered by searching through Mesh advanced search strategy and regular keywords with Boolean search strategy through multiple databases. The next step was screening the titles, and abstracts and only 166 papers passed through the full-text screening according to the inclusion and exclusion criteria. The quality of the included 166 studies was assessed using the Cochrane risk of bias tool for randomized trials. Finally, ten studies resulted from the qualitative synthesis and were included in this systematic review. Conclusion: combinatorial pharmacogenomics testing has the potential to be a useful tool in directing the treatment of depression in different age cohorts. In addition, it has a role in response improvement among patients with previous antidepressant failure.References
Ornstein SM, Nietert PJ, Jenkins RG, Litvin CB. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med. 2013 Sep-Oct;26(5):518-24. doi: 10.3122/jabfm.2013.05.130012.
Brody DJ, Gu Q. Antidepressant Use Among Adults: United States, 2015-2018. NCHS Data Brief. 2020 Sep;(377):1-8. https://pubmed.ncbi.nlm.nih.gov/33054926.
Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1;75(4):336-346. doi: 10.1001/jamapsychiatry.2017.4602.
Jameson JL, Longo DL. Precision medicine — personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.doi:10.1056/NEJMsb150310426014593.
Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507.doi:10.1038/nrg.2016.8627528417.
Tonelli MR, Shirts BH. Knowledge for precision medicine: mechanistic reasoning and methodological pluralism. JAMA. 2017;318(17):1649–1650. doi:10.1001/jama.2017.1191429052.
Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011 Aug;31(4):512-6. doi: 10.1097/JCP.0b013e3182228619.
Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008 Jan;75(1):57-66. doi: 10.3949/ccjm.75.1.57.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an Updated Guideline for Reporting Systematic Reviews. British Medical Journal. 2021 Mar 29;372(71). doi: 10.1136/bmj.n71.
Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928.
Forester BP, Parikh SV, Weisenbach S, et al. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Am J Geriatr Psychiatry. 2020 Sep;28(9):933-945. doi: 10.1016/j.jagp.2020.05.005. Epub 2020 May 19.
van der Schans, J., Hak, E., Postma, M, et al. Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial). Journal of Clinical Psychopharmacology, 39(6), 583-590. https://doi.org/10.1097/JCP.0000000000001129.
Vande Voort JL, Orth SS, Shekunov J, et al. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression. J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):46-55. doi: 10.1016/j.jaac.2021.03.011. Epub 2021 Jun 5.
Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 Apr;111:59-67. doi: 10.1016/j.jpsychires.2019.01.003. Epub 2019 Jan 4.
Thase ME, Parikh SV, Rothschild AJ, et al. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. J Clin Psychiatry. 2019 Oct 31;80(6):19m12910. doi: 10.4088/JCP.19m12910.
Papastergiou J, Quilty LC, Li W, et al. Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clin Transl Sci. 2021 Jul;14(4):1359-1368. doi: 10.1111/cts.12986. Epub 2021 Feb 28.
Tiwari AK, Zai CC, Altar CA, et al. Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Transl Psychiatry. 2022 Mar 14;12(1):101. doi: 10.1038/s41398-022-01847-8. Erratum in: Transl Psychiatry. 2022 May 30;12(1):214.
Perlis RH, Dowd D, Fava M, Lencz T, Krause DS. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety. 2020 Sep;37(9):834-841. doi: 10.1002/da.23029. Epub 2020 May 7.
McCarthy MJ, Chen Y, Demodena A, et al. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol. 2021 Aug;35(8):992-1002. doi: 10.1177/02698811211015224. Epub 2021 May 3.
Engelmann J, Zillich L, Frank J, et al. Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial. Transl Psychiatry. 2022 Jul 7;12(1):268. doi: 10.1038/s41398-022-02032-7.
